Edition:
United States

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

11.24EUR
14 Dec 2018
Change (% chg)

€-0.20 (-1.75%)
Prev Close
€11.44
Open
€11.52
Day's High
€11.52
Day's Low
€11.18
Volume
26,409
Avg. Vol
68,973
52-wk High
€15.00
52-wk Low
€10.54

Latest Key Developments (Source: Significant Developments)

Genomic Health and Biocartis expand collaboration to urology with the development of an idylla oncotype dx genomic prostate score test
Monday, 3 Dec 2018 04:51pm EST 

Dec 3 (Reuters) - Biocartis Group NV ::GENOMIC HEALTH AND BIOCARTIS EXPAND COLLABORATION TO UROLOGY WITH THE DEVELOPMENT OF AN IDYLLA ONCOTYPE DX GENOMIC PROSTATE SCORE TEST.GENOMIC HEALTH - AS PART OF AGREEMENT, CO WILL MAKE A PAYMENT OF EUR 2.5 MILLION TO BIOCARTIS, WHICH IS EXPECTED TO BE EXPENSED IN Q4 OF 2018.  Full Article

Biocartis Group And AstraZeneca Enter Into Agreement Aimed At Faster Lung Cancer Biomarker Results
Thursday, 29 Nov 2018 01:00am EST 

Nov 29 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS GROUP NV: BIOCARTIS AND ASTRAZENECA ENTER INTO AGREEMENT AIMED AT FASTER LUNG CANCER BIOMARKER RESULTS.PROSPECTIVE LUNG CANCER STUDY WITH IDYLLA(TM) EGFR MUTATION TEST (CE-IVD) WILL BE CONDUCTED IN SELECTED EUROPEAN COUNTRIES..STUDY IS AIMED AT DEMONSTRATING HOW UNIQUE FEATURES OF IDYLLA(TM) PLATFORM CAN OVERCOME CURRENT COMPLEXITY AND LONG TURNAROUND TIME FOR LUNG CANCER PATIENTS.STUDY WILL BE INITIATED AT MORE THAN A DOZEN SITES IN BELGIUM, FRANCE, GERMANY AND ITALY..  Full Article

Biocartis Group Announces Positive Study Results On Idylla Msi And Ras Liquid Biopsy Tests
Friday, 19 Oct 2018 01:00am EDT 

Oct 19 (Reuters) - BIOCARTIS GROUP NV ::RESULTS OF STUDY SHOWED IDYLLA(TM) LIQUID BIOPSY CTRAS-BRAF TESTS CAN PREDICT TREATMENT OUTCOME IN PATIENTS WITH MCRC.SECOND STUDY REVEALED POSITIVE PERFORMANCE OF PROTOTYPE IDYLLA(TM) MSI TEST BASED ON CONCORDANCE COMPARED TO OTHER TESTING METHODS FREQUENTLY USED.CONCORDANCE OF 98.7% WAS ACHIEVED WITH PROMEGA MSI ANALYSIS SYSTEM AND A CONCORDANCE OF 97.6% WITH IMMUNOHISTOCHEMICAL (IHC) ANALYSIS.SECOND STUDY DEMONSTRATES ROBUSTNESS OF IDYLLA(TM) MSI ASSAY, WHICH PROVIDES INFORMATION ON MSI STATUS OF TUMOR IN RAPID AND EASY WAY.THE STUDIES ON IDYLLA(TM) MSI AND RAS LIQUID BIOPSY TESTS TO BE PRESENTED AT ESMO CONGRESS.  Full Article

Biocartis Announces 2018 Half-Year Results On 6 September 2018
Thursday, 30 Aug 2018 01:00am EDT 

Aug 30 (Reuters) - Biocartis Group NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS ANNOUNCES 2018 HALF-YEAR RESULTS ON 6 SEPTEMBER 2018.  Full Article

Biocartis Obtains Exclusive Worldwide License Rights For EGFR Ectodomain Mutations
Tuesday, 28 Aug 2018 01:00am EDT 

Aug 28 (Reuters) - BIOCARTIS GROUP NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS OBTAINS EXCLUSIVE WORLDWIDE LICENSE RIGHTS FOR EGFR ECTODOMAIN MUTATIONS DETERMINING RESPONSE TO TARGETED COLORECTAL CANCER THERAPY.IS ENTITLED TO SUBLICENSE LICENSED RIGHTS TO THIRD PARTIES.NEW AGREEMENT IS CONVERSION OF EXISTING AGREEMENTS WITH HOSPITAL DEL MAR AND INVENTORS DR. BARDELLI AND DR. ARENA FROM UNIVERSITY OF TORINO.  Full Article

Biocartis Group Launches Innovative Idylla Msi Assay
Tuesday, 17 Jul 2018 01:00am EDT 

July 17 (Reuters) - Biocartis Group NV ::REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES INNOVATIVE IDYLLA(TM) MSI ASSAY.IDYLLA MSI ASSAY PROVIDES INFORMATION ON MSI STATUS (I.E. MSI-HIGH OR MICROSATELLITE STABLE) OF A TUMOR WITHIN APPROXIMATELY 150 MIN FROM JUST ONE SLICE OF FFPE TUMOR TISSUE, WITHOUT REQUIRING A REFERENCE SAMPLE.  Full Article

Biocartis' Idylla EGFR Mutation Test Able To Produce Result In 80 Percent Of Failed Next Generation Sequencing Lung Cancer Tests, According To Study
Monday, 28 May 2018 01:00am EDT 

May 28 (Reuters) - Biocartis Group NV ::STUDY DEMONSTRATES ABILITY OF IDYLLA(TM) EGFR MUTATION TEST TO PRODUCE A RESULT IN 80% OF FAILED NEXT GENERATION SEQUENCING LUNG CANCER TESTS.  Full Article

Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test
Wednesday, 24 Jan 2018 01:03am EST 

Jan 24 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS & IMMUNEXPRESS SIGN PARTNERSHIP FOR A SEPSIS HOST IMMUNE RESPONSE TEST ON THE IDYLLA™ PLATFORM.AGREEMENT TO DEVELOP, COMMERCIALIZE OF IMMUNEXPRESS’ SEPTICYPTE TEST FOR USE ON CO'S SAMPLETO-RESULT IDYLLA PLATFORM‍​.  Full Article

Biocartis And Amgen Sign New Agreement
Tuesday, 9 Jan 2018 01:01am EST 

Jan 9 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND.AGREEMENT AIMED AT DEVELOPMENT OF IDYLLA(TM) CDX BIOMARKER TESTS .FINANCIAL DETAILS ON NEW CDX AGREEMENT WITH AMGEN ARE NOT DISCLOSED..  Full Article

Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests
Monday, 4 Dec 2017 01:00am EST 

Dec 4 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS AND AMGEN <<>> SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS.BIOCARTIS -WILL PURSUE A PREMARKET APPROVAL FOR IDYLLA KRAS MUTATION TEST AND IDYLLA NRAS-BRAF MUTATION TEST WITH FDA​.‍AMGEN WILL PROVIDE FINANCIAL AND OPERATIONAL SUPPORT TO BIOCARTIS FOR PMA PROCESS​.‍AIM OF AGREEMENT IS TO REGISTER IDYLLA RAS BIOMARKER TESTS WITH US FDA AS COMPANION DIAGNOSTIC TEST FOR AMGEN'S DRUG VECTIBIX(PANITUMUMAB).​.  Full Article

Photo

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.